• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

Research Brief on 5-Amino-1-cyclopentyl-1H-pyrazol-3-ol (CAS: 436088-87-8): Recent Advances and Applications

The compound 5-Amino-1-cyclopentyl-1H-pyrazol-3-ol (CAS: 436088-87-8) has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of bioactive molecules, particularly in the development of kinase inhibitors and antimicrobial agents. This research brief aims to summarize the latest findings related to this compound, highlighting its synthetic pathways, biological activities, and potential clinical relevance.

One of the most notable advancements in the study of 5-Amino-1-cyclopentyl-1H-pyrazol-3-ol is its application in the design of selective kinase inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory activity against cyclin-dependent kinases (CDKs), which are critical targets in cancer therapy. The researchers utilized a structure-activity relationship (SAR) approach to optimize the compound's binding affinity, resulting in derivatives with improved selectivity and reduced off-target effects. These findings underscore the potential of 5-Amino-1-cyclopentyl-1H-pyrazol-3-ol as a scaffold for developing next-generation anticancer agents.

In addition to its role in kinase inhibition, recent research has also explored the antimicrobial properties of 5-Amino-1-cyclopentyl-1H-pyrazol-3-ol. A study published in Bioorganic & Medicinal Chemistry Letters (2024) reported that this compound and its analogs exhibit broad-spectrum activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The mechanism of action appears to involve disruption of bacterial cell wall synthesis, making it a promising candidate for addressing the growing challenge of antibiotic resistance. Further preclinical studies are underway to evaluate its pharmacokinetic and safety profiles.

The synthetic accessibility of 5-Amino-1-cyclopentyl-1H-pyrazol-3-ol has also been a focus of recent investigations. A novel, high-yield synthesis route was reported in Organic Process Research & Development (2023), which employs a one-pot cyclization strategy under mild conditions. This method not only improves the scalability of the compound but also reduces the environmental impact associated with traditional synthetic approaches. Such advancements are critical for facilitating the large-scale production of this compound for both research and potential clinical applications.

Looking ahead, the versatility of 5-Amino-1-cyclopentyl-1H-pyrazol-3-ol continues to inspire new research directions. Ongoing studies are exploring its utility in other therapeutic areas, such as neurodegenerative diseases and inflammatory disorders. Moreover, computational modeling and artificial intelligence-driven drug design are being leveraged to further optimize its pharmacological properties. As the body of evidence grows, this compound is poised to play an increasingly important role in the development of novel therapeutics.

In conclusion, 5-Amino-1-cyclopentyl-1H-pyrazol-3-ol (CAS: 436088-87-8) represents a promising scaffold in medicinal chemistry, with demonstrated applications in oncology, antimicrobial therapy, and beyond. The recent advancements in its synthesis, biological evaluation, and mechanistic understanding highlight its potential to address unmet medical needs. Future research should focus on translating these findings into clinical applications, while also exploring new derivatives with enhanced efficacy and safety profiles.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)